Network meta-analysis

Discontinuation due to gastrointestinal adverse events

Overweight or obesity without diabetes (adults)

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)Separate part 2 of a disconnected network

Randomized trials

Treatments

3,192

Participants

119

Events

In plain language

Across 9 trials with 3,192 participants, 0 of 19 treatments had a clearly better result than placebo on discontinuation due to gastrointestinal adverse events, 4 a clearly worse one, and for 15 the evidence could not tell them apart from placebo. The most favorable estimate was for HRS-7535 30 mg tablet once daily: hazard ratio (from event counts) 0.39 (95% credible interval 0.00 to 15.93).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
HRS-7535 30 mg tablet once daily HRS7535_PO_30MG_QD	0.39 (0.00 to 15.93)	0.00 to 15.87	Unclear
HRS-7535 120 mg tablet once daily HRS7535_PO_120MG_QD	0.42 (0.01 to 16.06)	0.01 to 16.63	Unclear
HRS-7535 60 mg tablet once daily HRS7535_PO_60MG_QD	0.43 (0.00 to 15.98)	0.00 to 16.58	Unclear
Ct388 sc 12mg qw CT388_SC_12MG_QW	0.59 (0.01 to 47.03)	0.01 to 50.01	Unclear
TG103 22.5 mg injection once weekly TG103_SC_22p5MG_QW	0.66 (0.01 to 56.03)	0.01 to 56.99	Unclear
TG103 15 mg injection once weekly TG103_SC_15MG_QW	0.67 (0.01 to 50.56)	0.01 to 52.47	Unclear
CT-388 7.5 mg injection once weekly CT388_SC_7p5MG_QW	0.69 (0.01 to 56.51)	0.01 to 57.83	Unclear
TG103 30 mg injection once weekly TG103_SC_30MG_QW	0.71 (0.01 to 47.02)	0.01 to 52.95	Unclear
Efpeglenatide 4 mg subcutaneous once weekly EFPE_SC_4MG_QW	1.09 (0.14 to 7.27)	0.12 to 7.99	Unclear
Aleniglipron 120 mg tablet once daily ALENIG_PO_120MG_QD	1.59 (0.25 to 10.99)	0.22 to 12.27	Unclear
Efpeglenatide 6 mg injection every 2 weeks EFPE_SC_6MG_Q2W	2.29 (0.43 to 13.14)	0.36 to 14.56	Unclear
Aleniglipron 90 mg tablet once daily ALENIG_PO_90MG_QD	2.75 (0.54 to 17.24)	0.47 to 20.13	Unclear
Mazdutide 16 mg injection once weekly MAZD_SC_16MG_QW	4.22 (0.34 to 123)	0.32 to 138	Unclear
Aleniglipron 45 mg tablet once daily ALENIG_PO_45MG_QD	4.92 (1.04 to 30.64)	0.91 to 34.20	Worse
Efpeglenatide 8 mg injection every 2 weeks EFPE_SC_8MG_Q2W	4.93 (1.12 to 26.43)	0.95 to 30.57	Worse
Semaglutide 2.4 mg subcutaneous once weekly SEMA_SC_2p4MG_QW	5.56 (2.31 to 15.14)	1.79 to 18.90	Worse
Efpeglenatide 6 mg subcutaneous once weekly EFPE_SC_6MG_QW	5.67 (1.33 to 29.34)	1.13 to 33.18	Worse
Liraglutide 3.0 mg subcutaneous once daily LIRA_SC_3p0MG_QD	10.28 (0.97 to 249)	0.87 to 267	Unclear
HRS-7535 180 mg tablet once daily HRS7535_PO_180MG_QD	12.95 (0.80 to 325)	0.74 to 348	Unclear

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	HRS7535_PO_30MG_QD	HRS7535_PO_120MG_QD	HRS7535_PO_60MG_QD	CT388_SC_12MG_QW	TG103_SC_22p5MG_QW	TG103_SC_15MG_QW	CT388_SC_7p5MG_QW	TG103_SC_30MG_QW	EFPE_SC_4MG_QW	ALENIG_PO_120MG_QD	EFPE_SC_6MG_Q2W	ALENIG_PO_90MG_QD	MAZD_SC_16MG_QW	ALENIG_PO_45MG_QD	EFPE_SC_8MG_Q2W	SEMA_SC_2p4MG_QW	EFPE_SC_6MG_QW	LIRA_SC_3p0MG_QD	HRS7535_PO_180MG_QD
PLACEBO	PLACEBO	2.56 0.06 to 208	2.39 0.06 to 182	2.31 0.06 to 208	1.68 0.02 to 179	1.52 0.02 to 178	1.49 0.02 to 142	1.45 0.02 to 158	1.41 0.02 to 169	0.92 0.14 to 7.37	0.63 0.09 to 3.99	0.44 0.08 to 2.34	0.36 0.06 to 1.84	0.24 0.01 to 2.90	0.20 0.03 to 0.97	0.20 0.04 to 0.89	0.18 0.07 to 0.43	0.18 0.03 to 0.75	0.10 0.00 to 1.03	0.08 0.00 to 1.24
HRS7535_PO_30MG_QD	0.39 0.00 to 15.93	HRS7535_PO_30MG_QD	0.95 0.00 to 278	0.97 0.00 to 286	0.65 0.00 to 293	0.56 0.00 to 246	0.56 0.00 to 220	0.54 0.00 to 236	0.54 0.00 to 246	0.36 0.00 to 26.11	0.24 0.00 to 15.50	0.16 0.00 to 9.70	0.14 0.00 to 8.80	0.08 0.00 to 8.63	0.08 0.00 to 4.62	0.08 0.00 to 4.47	0.07 0.00 to 3.16	0.07 0.00 to 3.85	0.03 0.00 to 3.52	0.03 0.00 to 1.45
HRS7535_PO_120MG_QD	0.42 0.01 to 16.06	1.05 0.00 to 295	HRS7535_PO_120MG_QD	1.03 0.00 to 274	0.69 0.00 to 289	0.63 0.00 to 263	0.60 0.00 to 249	0.59 0.00 to 240	0.60 0.00 to 247	0.39 0.00 to 25.33	0.26 0.00 to 16.83	0.18 0.00 to 9.86	0.14 0.00 to 8.34	0.09 0.00 to 8.48	0.08 0.00 to 4.45	0.08 0.00 to 4.38	0.07 0.00 to 3.12	0.07 0.00 to 4.13	0.04 0.00 to 3.11	0.03 0.00 to 1.50
HRS7535_PO_60MG_QD	0.43 0.00 to 15.98	1.03 0.00 to 302	0.97 0.00 to 273	HRS7535_PO_60MG_QD	0.67 0.00 to 264	0.60 0.00 to 299	0.59 0.00 to 213	0.57 0.00 to 243	0.60 0.00 to 245	0.38 0.00 to 29.56	0.26 0.00 to 16.27	0.18 0.00 to 9.68	0.14 0.00 to 8.33	0.09 0.00 to 9.14	0.08 0.00 to 4.57	0.08 0.00 to 4.66	0.07 0.00 to 3.33	0.07 0.00 to 3.65	0.04 0.00 to 3.23	0.03 0.00 to 1.44
CT388_SC_12MG_QW	0.59 0.01 to 47.03	1.53 0.00 to 824	1.45 0.00 to 616	1.49 0.00 to 724	CT388_SC_12MG_QW	0.88 0.00 to 714	0.84 0.00 to 525	0.82 0.00 to 474	0.86 0.00 to 505	0.56 0.00 to 64.76	0.35 0.00 to 45.21	0.24 0.00 to 29.45	0.20 0.00 to 21.89	0.13 0.00 to 20.97	0.12 0.00 to 13.10	0.11 0.00 to 12.46	0.10 0.00 to 9.37	0.10 0.00 to 9.94	0.05 0.00 to 8.11	0.04 0.00 to 8.14
TG103_SC_22p5MG_QW	0.66 0.01 to 56.03	1.77 0.00 to 797	1.58 0.00 to 829	1.67 0.00 to 943	1.13 0.00 to 846	TG103_SC_22p5MG_QW	0.96 0.00 to 492	0.92 0.00 to 612	0.95 0.00 to 602	0.61 0.00 to 88.32	0.41 0.00 to 49.72	0.28 0.00 to 32.21	0.23 0.00 to 25.34	0.14 0.00 to 24.49	0.13 0.00 to 14.74	0.13 0.00 to 15.05	0.11 0.00 to 10.02	0.11 0.00 to 12.46	0.06 0.00 to 8.88	0.05 0.00 to 9.18
TG103_SC_15MG_QW	0.67 0.01 to 50.56	1.78 0.00 to 740	1.66 0.00 to 892	1.69 0.00 to 737	1.20 0.00 to 644	1.05 0.00 to 643	TG103_SC_15MG_QW	0.99 0.00 to 527	0.95 0.00 to 508	0.63 0.00 to 71.24	0.42 0.00 to 45.82	0.30 0.00 to 29.10	0.24 0.00 to 25.64	0.15 0.00 to 21.79	0.13 0.00 to 13.42	0.13 0.00 to 12.88	0.12 0.00 to 9.73	0.12 0.00 to 10.74	0.06 0.00 to 9.03	0.05 0.00 to 8.00
CT388_SC_7p5MG_QW	0.69 0.01 to 56.51	1.85 0.00 to 1158	1.69 0.00 to 766	1.77 0.00 to 860	1.21 0.00 to 552	1.08 0.00 to 700	1.01 0.00 to 685	CT388_SC_7p5MG_QW	0.97 0.00 to 646	0.64 0.00 to 81.86	0.43 0.00 to 54.34	0.30 0.00 to 30.99	0.24 0.00 to 29.48	0.15 0.00 to 28.89	0.13 0.00 to 16.64	0.14 0.00 to 14.08	0.12 0.00 to 11.28	0.12 0.00 to 12.75	0.06 0.00 to 10.17	0.05 0.00 to 11.08
TG103_SC_30MG_QW	0.71 0.01 to 47.02	1.87 0.00 to 900	1.66 0.00 to 762	1.68 0.00 to 878	1.16 0.00 to 661	1.05 0.00 to 638	1.05 0.00 to 426	1.03 0.00 to 530	TG103_SC_30MG_QW	0.65 0.00 to 71.67	0.44 0.00 to 48.48	0.29 0.00 to 31.23	0.24 0.00 to 26.10	0.15 0.00 to 23.43	0.14 0.00 to 14.30	0.14 0.00 to 14.73	0.12 0.00 to 9.51	0.12 0.00 to 11.47	0.06 0.00 to 9.69	0.05 0.00 to 9.36
EFPE_SC_4MG_QW	1.09 0.14 to 7.27	2.77 0.04 to 335	2.55 0.04 to 306	2.63 0.03 to 326	1.80 0.02 to 267	1.63 0.01 to 271	1.58 0.01 to 212	1.55 0.01 to 248	1.53 0.01 to 241	EFPE_SC_4MG_QW	0.67 0.04 to 9.36	0.47 0.06 to 2.89	0.38 0.03 to 4.80	0.24 0.00 to 6.19	0.22 0.01 to 2.52	0.22 0.03 to 1.11	0.19 0.02 to 1.58	0.19 0.03 to 0.92	0.10 0.00 to 2.10	0.08 0.00 to 2.37
ALENIG_PO_120MG_QD	1.59 0.25 to 10.99	4.19 0.06 to 494	3.91 0.06 to 449	3.91 0.06 to 503	2.83 0.02 to 413	2.43 0.02 to 417	2.40 0.02 to 347	2.32 0.02 to 358	2.29 0.02 to 374	1.49 0.11 to 23.97	ALENIG_PO_120MG_QD	0.69 0.06 to 7.92	0.57 0.10 to 2.77	0.37 0.01 to 9.47	0.32 0.06 to 1.52	0.32 0.03 to 3.33	0.28 0.03 to 2.26	0.28 0.02 to 2.84	0.15 0.00 to 3.02	0.12 0.00 to 3.53
EFPE_SC_6MG_Q2W	2.29 0.43 to 13.14	6.17 0.10 to 650	5.54 0.10 to 594	5.65 0.10 to 624	4.16 0.03 to 566	3.56 0.03 to 573	3.36 0.03 to 460	3.32 0.03 to 516	3.41 0.03 to 548	2.13 0.35 to 15.41	1.44 0.13 to 18.15	EFPE_SC_6MG_Q2W	0.82 0.07 to 8.97	0.53 0.01 to 12.02	0.46 0.04 to 4.76	0.47 0.11 to 1.82	0.41 0.06 to 2.92	0.41 0.09 to 1.58	0.21 0.01 to 4.05	0.18 0.00 to 4.26
ALENIG_PO_90MG_QD	2.75 0.54 to 17.24	7.30 0.11 to 750	7.00 0.12 to 787	7.06 0.12 to 759	4.91 0.05 to 680	4.38 0.04 to 660	4.13 0.04 to 585	4.15 0.03 to 623	4.14 0.04 to 603	2.60 0.21 to 38.74	1.76 0.36 to 10.16	1.23 0.11 to 13.88	ALENIG_PO_90MG_QD	0.67 0.01 to 14.55	0.56 0.14 to 2.31	0.57 0.05 to 5.72	0.49 0.08 to 3.86	0.49 0.05 to 4.91	0.27 0.01 to 5.33	0.21 0.01 to 5.56
MAZD_SC_16MG_QW	4.22 0.34 to 123	12.09 0.12 to 2770	11.52 0.12 to 2508	11.27 0.11 to 2935	7.87 0.05 to 2068	7.01 0.04 to 1896	6.79 0.05 to 2038	6.64 0.03 to 2173	6.71 0.04 to 2115	4.16 0.16 to 214	2.70 0.11 to 126	1.89 0.08 to 80.26	1.49 0.07 to 68.16	MAZD_SC_16MG_QW	0.85 0.04 to 35.94	0.87 0.04 to 33.25	0.75 0.05 to 24.29	0.75 0.04 to 30.02	0.40 0.01 to 25.87	0.33 0.01 to 27.63
ALENIG_PO_45MG_QD	4.92 1.04 to 30.64	13.16 0.22 to 1498	12.32 0.22 to 1351	12.20 0.22 to 1452	8.67 0.08 to 1191	7.72 0.07 to 1227	7.49 0.07 to 1065	7.52 0.06 to 1093	7.29 0.07 to 1198	4.61 0.40 to 71.29	3.12 0.66 to 16.89	2.16 0.21 to 24.26	1.80 0.43 to 7.19	1.17 0.03 to 26.96	ALENIG_PO_45MG_QD	1.00 0.10 to 9.66	0.89 0.14 to 6.65	0.88 0.09 to 8.72	0.47 0.02 to 8.81	0.38 0.01 to 10.08
EFPE_SC_8MG_Q2W	4.93 1.12 to 26.43	13.11 0.22 to 1394	12.60 0.23 to 1220	12.38 0.21 to 1395	8.76 0.08 to 1142	7.72 0.07 to 1183	7.45 0.08 to 965	7.27 0.07 to 1024	7.34 0.07 to 1106	4.50 0.90 to 33.02	3.13 0.30 to 38.09	2.14 0.55 to 9.28	1.77 0.17 to 18.83	1.15 0.03 to 24.01	1.00 0.10 to 9.98	EFPE_SC_8MG_Q2W	0.87 0.15 to 6.06	0.87 0.27 to 2.84	0.47 0.01 to 8.87	0.38 0.01 to 10.08
SEMA_SC_2p4MG_QW	5.56 2.31 to 15.14	14.65 0.32 to 1351	13.81 0.32 to 1161	13.45 0.30 to 1330	9.65 0.11 to 1169	8.83 0.10 to 1070	8.17 0.10 to 936	8.27 0.09 to 922	8.08 0.11 to 1113	5.21 0.63 to 50.35	3.58 0.44 to 29.07	2.46 0.34 to 16.99	2.05 0.26 to 12.94	1.34 0.04 to 18.64	1.13 0.15 to 7.20	1.15 0.16 to 6.56	SEMA_SC_2p4MG_QW	1.00 0.15 to 5.71	0.54 0.02 to 7.03	0.43 0.02 to 7.84
EFPE_SC_6MG_QW	5.67 1.33 to 29.34	15.04 0.26 to 1655	14.19 0.24 to 1475	14.26 0.27 to 1596	10.36 0.10 to 1399	8.92 0.08 to 1346	8.52 0.09 to 1079	8.16 0.08 to 1207	8.36 0.09 to 1260	5.17 1.09 to 37.48	3.58 0.35 to 41.71	2.46 0.63 to 10.68	2.05 0.20 to 19.59	1.34 0.03 to 27.09	1.14 0.11 to 11.48	1.15 0.35 to 3.75	1.00 0.18 to 6.70	EFPE_SC_6MG_QW	0.53 0.02 to 10.13	0.44 0.01 to 10.79
LIRA_SC_3p0MG_QD	10.28 0.97 to 249	29.49 0.28 to 6029	27.05 0.32 to 5268	27.21 0.31 to 5742	19.73 0.12 to 4320	17.10 0.11 to 4498	16.75 0.11 to 3800	15.84 0.10 to 4064	16.46 0.10 to 4382	10.08 0.48 to 413	6.77 0.33 to 250	4.75 0.25 to 147	3.75 0.19 to 124	2.49 0.04 to 141	2.15 0.11 to 64.18	2.15 0.11 to 68.31	1.86 0.14 to 48.28	1.87 0.10 to 59.87	LIRA_SC_3p0MG_QD	0.81 0.01 to 48.99
HRS7535_PO_180MG_QD	12.95 0.80 to 325	32.10 0.69 to 5857	30.40 0.67 to 5558	30.86 0.69 to 5436	22.85 0.12 to 6826	22.15 0.11 to 5830	20.19 0.13 to 4943	20.13 0.09 to 6094	19.81 0.11 to 5699	12.40 0.42 to 566	8.27 0.28 to 363	5.61 0.23 to 203	4.72 0.18 to 188	2.99 0.04 to 185	2.62 0.10 to 101	2.63 0.10 to 88.44	2.33 0.13 to 66.52	2.26 0.09 to 75.72	1.24 0.02 to 70.58	HRS7535_PO_180MG_QD

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 0.200 (95% CrI 0.040 to 0.851), log scale
Residual deviance: 19.6 for 29 data points
DIC: 34.1 (pD 14.6)
Largest R-hat: 1.002
Smallest ESS: bulk 4,906, tail 4,588
Divergent transitions: 0
Convergence: All criteria met
Priors: PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-2.99, 1.74^2) on tau^2 (Withdrawals/drop-outs, pharm vs placebo control)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Sex (percent female) effect modifier, prognostic factor; 9 of 9	Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 8 of 9
STEP 1 S000144	74.07	13.33
STEP 5 S000214	77.6	0.65
NCT03041792 S000418	67.69	1.81
NCT02075281 S000743	76.35	8.49
ACCESS S000899	54.35	1.74
NCT05623839 S001559	50	not reported
NCT06250946 S002275	48.49	100 region: all sites in Asia
NCT04838405 S002824	56.25	12.5
NCT04855292 S003063	37.5	100 region: all sites in Asia

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Sex: design means range from 37.5 (PLACEBO vs TG103_SC_15MG_QW vs TG103_SC_22p5MG_QW vs TG103_SC_30MG_QW) to 76.3 (EFPE_SC_4MG_QW vs EFPE_SC_6MG_Q2W vs EFPE_SC_6MG_QW vs EFPE_SC_8MG_Q2W vs PLACEBO) percent female; threshold 15
FlagBaseline, Asian ancestry or region: design means range from 1.7 (ALENIG_PO_120MG_QD vs ALENIG_PO_45MG_QD vs ALENIG_PO_90MG_QD vs PLACEBO) to 100.0 (HRS7535_PO_120MG_QD vs HRS7535_PO_180MG_QD vs HRS7535_PO_30MG_QD vs HRS7535_PO_60MG_QD vs PLACEBO) percent Asian; threshold 30
NoteOutcome assessment, time point: selected time points span 6 to 111 weeks
NoteOutcome assessment, analysis set: mixed: randomized 1, safety 8
NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 8, while_on_treatment 1
NoteOutcome assessment, intercurrent events (rescue): mixed: not stated 8, treatment_policy 1
NoteData handling, input conversions: arms_combined 2

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
STEP 1	68	safety	not stated	not stated	not stated	not stated	while_on_treatment	treatment_policy	double_blind	industry	2018	adults; BMI 30 or more, or 27 or more with a weight related condition; no diabetes; HbA1c below 6.5 percent
STEP 5	111	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; HbA1c below 6.5 percent
NCT03041792	10.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; BMI 30 to 40; no diabetes; HbA1c below 6.5 percent
NCT02075281	20	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to 64 years; BMI 30 to 42, or 27 to 30 with comorbidity; FPG below 7 mmol/L; HbA1c 6.5 percent or less; no diabetes
ACCESS	36	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 79; BMI 30 or more, or 27 or more with comorbidity; HbA1c below 6.5 percent; weight above 80 kg; no diabetes
NCT05623839	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 70; BMI 27 to 50; HbA1c below 6.5 percent; no diabetes
NCT06250946	36	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 65; BMI 28 to 40; no diabetes, HbA1c below 6.5 percent
NCT04838405	6	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 65, BMI 25 or more (30 or more in cohorts 7 and 8), no diabetes
NCT04855292	14	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; BMI 26 or more; weight 60 kg or more; HbA1c below 6.5; no diabetes

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
STEP 1	A1	SEMA_SC_2p4MG_QW	68	arm, events	59 / 1,306		R0023399:Table 3
STEP 1	A2	PLACEBO	68	arm, events	5 / 655		R0023399:Table 3
STEP 5	A1	SEMA_SC_2p4MG_QW	111	arm, events	6 / 152		R0021896:Table 3
STEP 5	A2	PLACEBO	111	arm, events	1 / 152		R0021896:Table 3
NCT03041792	A1	LIRA_SC_3p0MG_QD	10.43	arm, events	4 / 32		R0023522:Results
NCT03041792	A2	PLACEBO	10.43	arm, events	0 / 29		R0023522:Results
NCT02075281	A1	PLACEBO	20	arm, events	1 / 60		R0011218:Supplement Table S6
NCT02075281	A2	EFPE_SC_4MG_QW	20	arm, events	2 / 59		R0011218:Supplement Table S6
NCT02075281	A3	EFPE_SC_6MG_QW	20	arm, events	9 / 59		R0011218:Supplement Table S6
NCT02075281	A4	EFPE_SC_6MG_Q2W	20	arm, events	4 / 59		R0011218:Supplement Table S6
NCT02075281	A5	EFPE_SC_8MG_Q2W	20	arm, events	8 / 60		R0011218:Supplement Table S6
ACCESS	A1	ALENIG_PO_45MG_QD	36	arm, events	6 / 45		R0000892:Table 2
ACCESS	A2	ALENIG_PO_90MG_QD	36	arm, events	5 / 65		R0000892:Table 2
ACCESS	A3	ALENIG_PO_120MG_QD	36	arm, events	3 / 64		R0000892:Table 2
ACCESS	A4	PLACEBO	36	arm, events	1 / 56		R0000892:Table 2
NCT05623839	A1	PLACEBO	27	arm, events	0 / 8		R0013210:Results
NCT05623839	A2+A3	MAZD_SC_16MG_QW	27	arm, events	3 / 24	arms_combined	R0013210:Results
NCT06250946	A1	PLACEBO	36	arm, events	0 / 46		R0001289:Supplement Table 6
NCT06250946	A2	HRS7535_PO_30MG_QD	36	arm, events	0 / 48		R0001289:Supplement Table 6
NCT06250946	A3	HRS7535_PO_60MG_QD	36	arm, events	0 / 47		R0001289:Supplement Table 6
NCT06250946	A4	HRS7535_PO_120MG_QD	36	arm, events	0 / 46		R0001289:Supplement Table 6
NCT06250946	A5	HRS7535_PO_180MG_QD	36	arm, events	2 / 48		R0001289:Supplement Table 6
NCT04838405	A10+A9	CT388_SC_12MG_QW	6	arm, events	0 / 12	arms_combined	R0007991:Table 3
NCT04838405	A7	PLACEBO	6	arm, events	0 / 6		R0007991:Table 3
NCT04838405	A8	CT388_SC_7p5MG_QW	6	arm, events	0 / 6		R0007991:Table 3
NCT04855292	A1	TG103_SC_15MG_QW	14	arm, events	0 / 12		R0022276:Results
NCT04855292	A2	TG103_SC_22p5MG_QW	14	arm, events	0 / 12		R0022276:Results
NCT04855292	A3	TG103_SC_30MG_QW	14	arm, events	0 / 12		R0022276:Results
NCT04855292	A4	PLACEBO	14	arm, events	0 / 12		R0022276:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab